Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Bennett

Showing results (551-560 of 566) with videos related to

Pageof 57
Sort By:
Frontiers in Cardiovascular Medicine|December 14, 2023
Multicenter registry and test bed for extended outpatient hemodynamic monitoring: the hemodynamic frontiers in heart failure (HF<sup>2</sup>) initiativeJ Thomas Heywood, Kartik Munshi, Timothy Jordan, et al.
Chemistry & Biology|October 30, 2003
Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide libraryYasumichi Hitoshi, Tarikere Gururaja, Denise M Pearsall, et al.
Nature Neuroscience|October 16, 2001
A candidate gene for human neurodegenerative disorders: a rat PKC gamma mutation causes a Parkinsonian syndromeN J Craig, M B Durán Alonso, K L Hawker, et al.
Cancer Research|July 10, 2007
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeSusan D Demo, Christopher J Kirk, Monette A Aujay, et al.
JAMA|July 4, 2002
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trialScott M Hammer, Florin Vaida, Kara K Bennett, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironmentSusanne M Steggerda, Mark K Bennett, Jason Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Molecular Cancer Therapeutics|February 14, 2014
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancerMatt I Gross, Susan D Demo, Jennifer B Dennison, et al.
Journal of Medicinal Chemistry|April 8, 2009
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)Han-Jie Zhou, Monette A Aujay, Mark K Bennett, et al.
Circulation|March 31, 2010
Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working groupKim A Eagle, Geoffrey S Ginsburg, Kiran Musunuru, et al.
Pageof 57

Showing results (551-560 of 566) with videos related to

Sort By:
Pageof 57
Frontiers in Cardiovascular Medicine|December 14, 2023
Multicenter registry and test bed for extended outpatient hemodynamic monitoring: the hemodynamic frontiers in heart failure (HF<sup>2</sup>) initiativeJ Thomas Heywood, Kartik Munshi, Timothy Jordan, et al.
Chemistry & Biology|October 30, 2003
Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide libraryYasumichi Hitoshi, Tarikere Gururaja, Denise M Pearsall, et al.
Nature Neuroscience|October 16, 2001
A candidate gene for human neurodegenerative disorders: a rat PKC gamma mutation causes a Parkinsonian syndromeN J Craig, M B Durán Alonso, K L Hawker, et al.
Cancer Research|July 10, 2007
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeSusan D Demo, Christopher J Kirk, Monette A Aujay, et al.
JAMA|July 4, 2002
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trialScott M Hammer, Florin Vaida, Kara K Bennett, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironmentSusanne M Steggerda, Mark K Bennett, Jason Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Molecular Cancer Therapeutics|February 14, 2014
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancerMatt I Gross, Susan D Demo, Jennifer B Dennison, et al.
Journal of Medicinal Chemistry|April 8, 2009
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)Han-Jie Zhou, Monette A Aujay, Mark K Bennett, et al.
Circulation|March 31, 2010
Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working groupKim A Eagle, Geoffrey S Ginsburg, Kiran Musunuru, et al.
Pageof 57